Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand
Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product WegovyBusiness live – latest updatesNovo Nordisk is to invest more than $4bn (£3.2bn) in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic.Denmark’s biggest pharmaceuticals company said it would spend $4.1bn building a second filling and finishing facility in Clayton, North Carolina, one of the biggest manufacturing investments in its history. Its drugs are injected by users once a week, and come in pre-filled pens. Continue reading...
![Ozempic maker Novo Nordisk invests $4bn to meet US ‘skinny jab’ demand](https://i.guim.co.uk/img/media/7cff548f5f21f1aaffc0ec265d01f83c2faa6583/0_208_6234_3740/master/6234.jpg?width=140&quality=85&auto=format&fit=max&s=a3f29bc122681aba1e6470a0ea1355be#)
Pharma group plans plant in North Carolina to produce diabetes drug and weight-loss product Wegovy
Novo Nordisk is to invest more than $4bn (£3.2bn) in US manufacturing as it battles to keep up with booming demand for its obesity and diabetes drugs Wegovy and Ozempic.
Denmark’s biggest pharmaceuticals company said it would spend $4.1bn building a second filling and finishing facility in Clayton, North Carolina, one of the biggest manufacturing investments in its history. Its drugs are injected by users once a week, and come in pre-filled pens. Continue reading...